AstraZeneca Pharma India has received CDSCO approval to sell and distribute Durvalumab (Imfinzi) for an additional cancer indication, expanding treatment options for endometrial cancer patients. https://english.mathrubhumi.com/lifestyle/health/astrazeneca-cdsco-approval-durvalumab-new-cancer-indication-wbbem2rw?utm_source=dlvr.it&utm_medium=mastodon #AstraZeneca #Durvalumab #Imfinzi #CDSCO #CancerTreatment

💊💉 #durvalumab SmPC for IMFINZI 50 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.5 Nature; 6.6 Special precautions for disposal; Revised: 09 December ...

💊💉 #durvalumab SmPC for IMFINZI 50 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.5 Nature; 6.6 Special precautions for disposal; Revised: 09 December ...

💊💉 #durvalumab SmPC for IMFINZI 50 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.5 Nature; 6.6 Special precautions for disposal; Revised: 09 December ...

💊💉 #durvalumab SmPC for IMFINZI 50 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.5 Nature; 6.6 Special precautions for disposal; Revised: 09 December ...

💊💉 #durvalumab SmPC for IMFINZI 50 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.5 Nature; 6.6 Special precautions for disposal; Revised: 09 December ...

💊💉 #durvalumab SmPC for IMFINZI 50 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.5 Nature; 6.6 Special precautions for disposal; Revised: 09 December ...

💊💉 #durvalumab SmPC for IMFINZI 50 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.5 Nature; 6.6 Special precautions for disposal; Revised: 09 December ...

💊💉 #durvalumab SmPC for IMFINZI 50 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.5 Nature; 6.6 Special precautions for disposal; Revised: 09 December ...

💊💉 #durvalumab SmPC for IMFINZI 50 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.5 Nature; 6.6 Special precautions for disposal; Revised: 09 December ...